Año: 2024
Journal Impact Factor (JIF): 3.30
| Categoría | Edición | Posición | Cuartil | Tercil | Decil |
|---|---|---|---|---|---|
| INFECTIOUS DISEASES | ESCI | 41/137 | Q2 | T1 | D3 |
| PHARMACOLOGY & PHARMACY | ESCI | 122/352 | Q2 | T2 | D4 |
| MICROBIOLOGY | ESCI | 74/163 | Q2 | T2 | D5 |
Año: 2024
Journal Citation Indicator (JCI): 0,810
| Categoría | Posición | Cuartil | Tercil | Decil | Percentil |
|---|---|---|---|---|---|
| INFECTIOUS DISEASES | 50/137 | Q2 | T2 | D4 | 63,87 |
| MICROBIOLOGY | 68/163 | Q2 | T2 | D5 | 58,59 |
| PHARMACOLOGY & PHARMACY | 117/353 | Q2 | T1 | D4 | 67,00 |
Año:
2024
CiteScore:
6,100
| Categoría | Posición | Cuartil | Tercil | Decil |
|---|---|---|---|---|
| Infectious Diseases | 93/357 | Q2 | T1 | D3 |
| Microbiology | 75/188 | Q2 | T2 | D4 |
| Microbiology (medical) | 52/148 | Q2 | T2 | D4 |
| Immunology | 109/240 | Q2 | T2 | D5 |
| Immunology and Allergy | 94/231 | Q2 | T2 | D5 |
SJR año:
2024
Factor de Impacto:
1,063
| Categoría | Posición | Cuartil | Tercil | Decil |
|---|---|---|---|---|
| Infectious Diseases | 71/361 | Q1 | T1 | D2 |
| Microbiology (medical) | 32/150 | Q1 | T1 | D3 |
| Microbiology | 53/185 | Q2 | T1 | D3 |
| Immunology | 94/245 | Q2 | T2 | D4 |
| Immunology and Allergy | 82/233 | Q2 | T2 | D4 |
| Agencia | Código de Proyecto |
|---|---|
| Pfizer | - |
| United States Department of Health and Human Services | - |
| # | Autor | Afiliación |
|---|---|---|
| 1 | National & Kapodistrian University of Athens (Greece) | |
| 2 | Cisneros, JM | CSIC-JA-USE - Instituto de Biomedicina de Sevilla (IBIS) (Spain) |
| 3 | Carmeli, Y | Tel Aviv Sourasky Medical Center (Israel) |
| 4 | Wang, MG | Huashan Hospital Fudan University; Natl Heath Commiss Peoples Republ China (Peoples R China) |
| 5 | Leong, CL | Hosp Kuala Lumpur (Malaysia) |
| 6 | Pontikis, K | Gen & Chest Dis Hosp Sotiria (Greece) |
| 7 | Anderzhanova, A | SBHI City Moscow NI Pirogov City Clin Hosp 1 (Russia) |
| 8 | Florescu, S | Carol Davila University of Medicine & Pharmacy; Victor Babes National Institute of Pathology (Romania) |
| 9 | Kozlov, R | Ministry of Health of the Russian Federation (Russia) |
| 10 | Rodriguez-Noriega, E | Hosp Civil Guadalajara Fray Antonio Alcalde (Mexico) |
| 11 | Psichogiou, M | Laiko General Hospital (Greece) |
| 12 | Rattanaumpawan, P | Siriraj Hospital (Thailand) |
| 13 | Streinu-Cercel, A | Carol Davila University of Medicine & Pharmacy; National Institute for Infectious Diseases "Matei Bals" (Romania) |
| 14 | Ramasubramanian, V | Apollo Hosp (India) |
| 15 | Arhin, FF | Pfizer Canada (Canada) |
| 16 | Rogers, H | Pfizer USA (USA) |
| 17 | Wible, M | Pfizer Inc Global Prod Dev (USA) |
| 18 | Leaney, J | Pfizer United Kingdom (England) |
| 19 | Jacobson, D | MICROSOFT ISRAEL (Israel) |
| 20 | Pypstra, R | Pfizer USA (USA) |
| 21 | Chow, JW | Pfizer Inc Global Prod Dev (USA) |